ESR1 and invasive breast carcinoma: Approximately 10-20% of women with invasive breast cancer have tumors that are histopathologically negative for the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER-2) [1-3].